Bispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells
Published in Current Pharmaceutical Biotechnology
Targeted cellular immunotherapy with bifunctional antibodies (bsAbs) has emerged as a promising therapeutic approach for cancer over the last two decades. Progress in antibody engineering has led to the generation of many different types of antibody-derived entities that display at least two binding specificities. Most bsAbs consist of large IgG-li...
